Analysts Set Monopar Therapeutics Inc. (NASDAQ:MNPR) Target Price at $112.08

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) have earned an average rating of “Buy” from the fourteen analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, ten have assigned a buy rating and three have assigned a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $112.0833.

A number of brokerages have recently commented on MNPR. Cantor Fitzgerald reiterated an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, July 15th. UBS Group set a $125.00 price target on shares of Monopar Therapeutics in a research report on Thursday, July 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, July 12th. Finally, Piper Sandler set a $105.00 price objective on shares of Monopar Therapeutics in a report on Tuesday, June 2nd.

Get Monopar Therapeutics alerts:

Get Our Latest Stock Report on Monopar Therapeutics

Institutional Investors Weigh In On Monopar Therapeutics

A number of large investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. acquired a new stake in shares of Monopar Therapeutics in the first quarter valued at approximately $673,000. Jane Street Group LLC acquired a new position in Monopar Therapeutics during the first quarter worth $377,000. Geode Capital Management LLC boosted its stake in Monopar Therapeutics by 99.7% during the second quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock worth $3,468,000 after buying an additional 48,379 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after buying an additional 1,821 shares in the last quarter. Finally, Rhumbline Advisers purchased a new stake in Monopar Therapeutics in the 2nd quarter valued at $209,000. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

Monopar Therapeutics Stock Performance

Shares of MNPR opened at $114.66 on Tuesday. Monopar Therapeutics has a one year low of $29.18 and a one year high of $116.64. The stock has a market capitalization of $768.22 million, a price-to-earnings ratio of -60.35 and a beta of 1.46. The stock has a 50 day moving average price of $84.55 and a 200 day moving average price of $68.03.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.41. On average, analysts predict that Monopar Therapeutics will post -2.82 earnings per share for the current year.

About Monopar Therapeutics

(Get Free Report)

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

Featured Stories

• Five stocks we like better than Monopar Therapeutics
• Microsoft Just Flipped the AI Spending Narrative Overnight
• Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
• Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
• Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes

Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.